K36’s program is the first to study the promise of targeting the methyltransferase nuclear receptor SET domain-containing 2 (NSD2, also known as MMSET) for the treatment of hematologic and solid tumor malignancies. By targeting NSD2, K36’s clinical pipeline aims to specifically address an underlying driver of cancer in multiple types of malignancies.

​

KTX-1001 is a first-in-class, oral, highly selective inhibitor of MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to the t(4;14) translocation. A clinical trial of KTX-1001, K36-MMSET-001 is actively enrolling multiple myeloma patients in the United States, Canada and Europe. Preliminary data presented in December 2024 demonstrated evidence of clinical activity of KTX-1001 in multiple myeloma patients.

The K36-STRIKE-001 trial studies the oral, selective NSD2 inhibitor (KTX-2001) for patients with metastatic castration-resistant prostate cancer (mCRPC) both as monotherapy and in combination with the androgen receptor pathway inhibitor darolutamide will be open in the US in 3Q25.